Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20,089 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC. Lapalombella R, et al. Among authors: jin y. Clin Cancer Res. 2008 Jan 15;14(2):569-78. doi: 10.1158/1078-0432.CCR-07-1006. Clin Cancer Res. 2008. PMID: 18223233
Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia.
Jin Y, Liu S, Yu B, Golan S, Koh CG, Yang J, Huynh L, Yang X, Pang J, Muthusamy N, Chan KK, Byrd JC, Talmon Y, Lee LJ, Lee RJ, Marcucci G. Jin Y, et al. Mol Pharm. 2010 Feb 1;7(1):196-206. doi: 10.1021/mp900205r. Mol Pharm. 2010. PMID: 19852511 Free PMC article.
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
Yu B, Mao Y, Bai LY, Herman SE, Wang X, Ramanunni A, Jin Y, Mo X, Cheney C, Chan KK, Jarjoura D, Marcucci G, Lee RJ, Byrd JC, Lee LJ, Muthusamy N. Yu B, et al. Among authors: jin y. Blood. 2013 Jan 3;121(1):136-47. doi: 10.1182/blood-2012-01-407742. Epub 2012 Nov 19. Blood. 2013. PMID: 23165478 Free PMC article.
Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.
Huang X, Schwind S, Santhanam R, Eisfeld AK, Chiang CL, Lankenau M, Yu B, Hoellerbauer P, Jin Y, Tarighat SS, Khalife J, Walker A, Perrotti D, Bloomfield CD, Wang H, Lee RJ, Lee LJ, Marcucci G. Huang X, et al. Among authors: jin y. Oncotarget. 2016 Sep 13;7(37):59273-59286. doi: 10.18632/oncotarget.11150. Oncotarget. 2016. PMID: 27517749 Free PMC article.
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.
Eisenmann ED, Fu Q, Muhowski EM, Jin Y, Uddin ME, Garrison DA, Weber RH, Woyach J, Byrd JC, Sparreboom A, Baker SD. Eisenmann ED, et al. Among authors: jin y. Cancer Res Commun. 2021 Nov;1(2):79-89. doi: 10.1158/2767-9764.crc-21-0076. Epub 2021 Nov 9. Cancer Res Commun. 2021. PMID: 34950932 Free PMC article.
In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors.
Uddin ME, Talebi Z, Chen S, Jin Y, Gibson AA, Noonan AM, Cheng X, Hu S, Sparreboom A. Uddin ME, et al. Among authors: jin y. Pharmaceutics. 2021 Nov 25;13(12):2004. doi: 10.3390/pharmaceutics13122004. Pharmaceutics. 2021. PMID: 34959286 Free PMC article.
20,089 results
You have reached the last available page of results. Please see the User Guide for more information.